AACR Award Targets Younger Ca Researchers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 10
Volume 4
Issue 10

PHILADELPHIA-The American Association for Cancer Research (AACR) is sponsoring its fourth annual Gertrude Elion Cancer Research Award. This award, provided through an educational grant from Glaxo Wellcome Oncology, is open to nontenured cancer investigators in clinical, basic, or translational research in the United States and Canada.

PHILADELPHIA-The American Association for Cancer Research (AACR)is sponsoring its fourth annual Gertrude Elion Cancer ResearchAward. This award, provided through an educational grant fromGlaxo Wellcome Oncology, is open to nontenured cancer investigatorsin clinical, basic, or translational research in the United Statesand Canada.

The application deadline is February 15, 1996, and the award willbe presented at the AACR annual meeting in Washington, DC, inApril, 1996.

The award recipient must have completed postdoctoral studies orclinical fellowships no later than July 1, 1996, and ordinarilynot more than 5 years prior to the award year. The 1-year awardincludes a $30,000 grant plus travel to the AACR annual meeting.

For more information, contact Jenny Anne Horst-Martz at the AACRin Philadelphia. Phone: 215-440-9300; Email: aacr@aol.com.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content